Table 3.

Sensitivity analysis

	R2 (95% CI)	P value	STE
Total population [5–10, 17–24, 34–39]			0.96
Sample size	0.80 (0.49 to 0.99)	<  0.001
Fixed effect	0.82 (0.52 to 0.99)	<  0.001
Random effect	0.82 (0.52 to 0.99)	<  0.001
Phase 3 trials [5–10, 18–20, 22, 34–36, 38, 39]			0.96
Sample size	0.82 (0.48 to 0.99)	<  0.001
Fixed effect	0.82 (0.49 to 0.99)	<  0.001
Random effect	0.83 (0.50 to 0.99)	<  0.001
Trials with overall included patients ≥ 200 [7, 10, 18–20, 36, 38, 39]			0.93
Sample size	0.85 (0.41 to 0.99)	<  0.001
Fixed effect	0.86 (0.41 to 0.99)	<  0.001
Random effect	0.87 (0.44 to 0.99)	<  0.001
Trials with median follow-up ≥ 24 months [6, 7, 9, 10, 18–23, 34, 36, 38, 39]			0.95
Sample size	0.80 (0.43 to 0.99)	<  0.001
Fixed effect	0.81 (0.45 to 0.99)	<  0.001
Random effect	0.80 (0.43 to 0.99)	<  0.001
Trials with adjuvant therapy versus observation [5–9, 20, 34, 35]			0.81
Sample size	0.68 (0.17 to 0.99)	0.006
Fixed effect	0.69 (0.18 to 0.99)	0.005
Random effect	0.73 (0.22 to 0.99)	0.003
Trials with adjuvant therapy versus adjuvant therapy [8, 17–19, 21–24, 36, 38, 39]			0.96
Sample size	0.90 (0.59 to 0.99)	<  0.001
Fixed effect	0.93 (0.66 to 0.99)	<  0.001
Random effect	0.89 (0.58 to 0.99)	<  0.001

R² coefficient of determination, STE surrogate threshold effect